 | | Vol. 6.42 – 30 November, 2020 |
| |
|
|
| Children with Fanconi anemia (FA) are a paradigm for extreme Squamous cell carcinoma susceptibility caused by germline loss-of-function mutations in FA DNA repair pathway genes. To discover epidermal vulnerabilities, patient-derived pluripotent stem cells (PSCs) conditional for the FA pathway were differentiated into epidermal stem and progenitor cells and PSC-derived epidermal organotypic rafts.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
| | The authors performed single-cell RNA sequencing of human eyelid skin from healthy individuals across different ages and identified 11 canonical cell types, as well as six subpopulations of basal cells.
[Developmental Cell] |
| | Researchers showed that inhibition of PDK1 in senescent human dermal fibroblasts eradicated senescence hallmarks and restored entry into the cell cycle by suppressing both nuclear factor κB and mTOR signaling, resulting in restored skin regeneration capacity.
[Proceedings of the National Academy of Sciences of the United States of America] |
| | Scientists demonstrated that miR-93-3p was significantly up-regulated using an in vivo mouse skin wound healing model, there was no change in the expression of miR-93-5p during skin wound healing. In HaCaT cells, miR-93-3p overexpression increased proliferation and migration of the cells, whereas miR-93-3p inhibition had the reverse effect.
[Molecular Therapy-Nucleic Acids] |
| | Investigators generated a novel model of bioartificial human dermis substitute by tissue engineering to treat infected wounds using fibrin-agarose biomaterials functionalized with NLCs loaded with two anti-Pseudomonas antibiotics: sodium colistimethate and amikacin.
[Journal of Nanobiotechnology] |
| | To address the role of the internalization mode, scientists performed infection studies at low temperatures as a tool to interfere with endocytic pathways. Successful Herpes simplex virus-1 entry in primary human keratinocytes and HaCaT cells were observed even at 7°C, although delayed compared to infection at 37°C.
[Journal of Virology] |
| |
|
|
| Investigators investigated the role of uPAR in melanoma cell lines-derived exosomes and their pro-angiogenic effects on human microvascular endothelial cells and endothelial colony-forming cells.
[Cellular and Molecular Life Sciences] |
|
|
|
| The authors mimicked the interaction of tumor cells with liver cells and peripheral blood mononuclear cells in vitro, and compared newly secreted extracellular vesicle (EV)-associated miRNAs and protein factors with those detected in melanoma patient`s plasma EV.
[Ebiomedicine] |
|
|
|
| Researchers showed the effect of calcium electroporation on immune cells, using melanoma-conditioned bone marrow-derived macrophages.
[Scientific Reports] |
|
|
|
|
| The authors discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.
[Nature] |
|
|
|
| Investigators discuss the recent advances in the field of epigenetics of non-melanoma skin cancer. Particularly, the roles of DNA methylation, histone hyperacetylation, and non-coding RNA such as long-chain noncoding RNAs, circular RNAs, and miRNA in the disease progression are summarized.
[Seminars in Cancer Biology] |
|
|
|
|
| Janssen announced that the European Commission approved TREMFYA® for the treatment of adult patients with active PsA who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.
[Janssen Pharmaceutical Companies of Johnson & Johnson (Business Wire. Inc.)] |
|
|
|
| The European Commission extended the marketing authorization for Dupixent® in the European Union (EU) to include children six to eleven years of age with severe atopic dermatitis who are candidates for systemic therapy. Dupixent® is the only systemic medicine approved in the EU to treat these patients.
[European Commission (Globe Newswire Inc.)] |
|
|
|
|
| May 30 – June 4, 2021
New London, New Hampshire, United States |
|
|
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | Universitätsklinikum Carl Gustav Carus Dresden – Dresden, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
